The study suggests that long-term follow-up and management of patients is crucial after COVID-19.
In a population-based study published in JAMA Dermatology, Researchers from the Republic of Korea investigated whether a history of coronavirus disease 2019 (COVID-19) increased the long-term risk of autoimmune and autoinflammatory connective tissue disorders.
They found a significantly higher risk of developing autoimmune and autoinflammatory conditions, such as rheumatoid arthritis (RA), lupus, Crohn’s disease and alopecia, among people who had COVID-19, with risks especially elevated for those with severe cases, variant infections Delta , and those who were unvaccinated.
Background
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not only led to immediate health problems but may also lead to long-term autoimmune and autoinflammatory diseases. While acute effects such as respiratory and cardiovascular problems are well known, the potential for COVID-19 to trigger autoimmune responses through mechanisms such as immune cross-reactivity is less understood.
Evidence shows that the virus can disrupt self-tolerance in the immune system, producing autoantibodies linked to conditions such as inflammatory arthritis and Guillain-Barré syndrome. Recent studies show an increased risk of autoimmune connective tissue diseases such as lupus, rheumatoid arthritis, Crohn’s disease and alopecia areata among COVID-19 survivors. However, previous studies were limited by short follow-up times, which could miss the gradual onset of these diseases. Long-term research is needed to fully understand the impact of COVID-19 on autoimmune disease risk and to guide ongoing health monitoring.
Therefore, the researchers in the present study used an extended observation period to assess the long-term risk of developing autoimmune and autoinflammatory diseases after COVID-19.
About the study
Using the National Health Insurance Service (NHIS) database and the Korea Disease Control and Prevention Agency’s COVID-19 registry, the researchers in the present study analyzed 6,912,427 participants. Of these, 3,145,388 participants had COVID-19 and 3,767,039 were controls, both with at least 180 days of observation. The sample was balanced for demographic and health factors and had a mean age of 53.39 years and 46.4% of participants were female.
COVID-19 was confirmed by a polymerase chain reaction test or physician-confirmed rapid antigen test. Outcomes were measured by tracking autoimmune disease diagnoses (requiring at least three physician visits) and assessed using codes from the tenth revision of the International Classification of Diseases (ICD-10). Inverse probability of treatment weighting (IPTW) was used to balance cohorts based on demographic, socioeconomic, lifestyle, and comorbidity data.
Cox proportional hazards models were used to analyze risks, adjusted for factors such as age, sex, severity of COVID-19, periods of variation (Delta or Omicron), and vaccination status. Sensitivity analyzes were conducted to address any potential diagnostic issues and underreporting, compared with a pre-pandemic historical control group.
Results and discussion
According to the study, patients with COVID-19 showed an increased risk for a number of autoimmune diseases, including alopecia areata (adjusted Harard ratio [AHR]1.11), vitiligo (AHR, 1.11), Behçet’s disease (AHR, 1.45), Crohn’s disease (AHR, 1.35), RA (AHR, 1.09), alopecia wereata (AHR, 1, 24), ulcerative colitis (AHR, 1.15), Sjögren’s syndrome (AHR, 1.13), systemic lupus erythematosus (SLE) (AHR, 1.14), ankylosing spondylitis (AHR, 1.11) and bullous pemphigoid (AHR, 1.62).
Men with COVID-19 were more prone to develop alopecia areata, vitiligo, and rheumatoid arthritis, while women had increased risks of alopecia areata, Behçet’s disease, and bullous pemphigoid. Analyzes based on age showed that participants under 40 had a higher risk of autoimmune conditions such as alopecia areata and ulcerative colitis, while those over 40 were at risk for conditions such as Sjögren’s syndrome, SLE and ankylosing spondylitis .
The severity of COVID-19 was found to influence autoimmune risks, with intensive care patients having a significantly higher risk of sarcoidosis, Sjögren’s syndrome, and bullous pemphigoid. The Delta-dominated period had higher risks for autoimmune diseases than the Omicron period. Vaccination appeared to moderate autoimmune risks, with unvaccinated patients being more susceptible to conditions such as RA, SLE and Crohn’s disease. Sensitivity analyzes with historical controls (pre-pandemic) confirmed similar trends, indicating the robustness of the results.
Positive control outcomes, such as heart failure, were consistent with known effects of COVID-19, while negative controls (eg, epidermal cysts) showed no significant association, strengthening the validity of the study. Overall, COVID-19 was associated with increased risks for various autoimmune diseases, especially among elderly, unvaccinated, or severely affected individuals.
An extensive follow-up strengthens the study, which uses large-scale national data, takes into account a wide range of covariates and uses stratified analyzes to identify risk subgroups. However, the generalizability of the study may be limited due to single ethnicity, potential confounding limitations, selection bias from untested or asymptomatic cases, and low incidence rates for some diseases affecting statistical significance.
Conclusion
In conclusion, the study highlighted the long-term risks of autoimmune and autoinflammatory connective tissue disorders in patients with COVID-19, emphasizing the importance of continued vigilance and research into the potential effects of COVID-19. Going forward, it is important to identify subgroup-specific vulnerabilities and disease patterns to address the pandemic’s lasting impact on global health.
